This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy
Scientific Reports Open Access 07 July 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY et al. High-dose chemotherapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 1987; 316: 1493–1498.
Hagberg H, Gisselbrecht C, CORAL study group. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol 2006; 17 Suppl 4: iv31–iv32.
Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297.
Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem cell support. N Engl J Med 2004; 350: 1287–1295.
Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol, a Groupe d’Etude des Lymphomes de l’Adulte study. J Clin Oncol 2000; 18: 3025–3030.
Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, López-Guillermo A, Gisselbrecht C et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793–800.
Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K et al. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Ann Hematol 2014; 93: 233–242.
Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH . BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 1995; 13: 588–595.
Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451–458.
Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419–3425.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203–1210.
Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood 2014; 124: 3029–3031.
Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A et al. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood 2014; 124: 2306–2312.
Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S et al. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 831–837.
Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle K et al. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs 2007; 18: 587–595.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Garciaz, S., Coso, D., Schiano de Collela, JM. et al. Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity. Bone Marrow Transplant 51, 319–321 (2016). https://doi.org/10.1038/bmt.2015.257
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.257
This article is cited by
-
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study
Bone Marrow Transplantation (2022)
-
BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy
Scientific Reports (2021)
-
Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen
Bone Marrow Transplantation (2019)
-
High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation
Bone Marrow Transplantation (2019)
-
Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review
Bone Marrow Transplantation (2017)